国家医保局：严肃核查处置定点药店“阴阳价格”问题

Core Viewpoint - The National Healthcare Security Administration emphasizes the need for strict monitoring and investigation of discriminatory pricing practices ("yin-yang pricing") in designated retail pharmacies, where the same medication is sold at higher prices to insured patients compared to uninsured patients [1][2] Group 1: Monitoring and Investigation - Local healthcare departments are required to focus on reports of "yin-yang pricing" and conduct thorough investigations into these practices [1] - Designated pharmacies are to be included in a key monitoring list for their pricing behaviors, with self-inspections mandated to identify and rectify any issues [1] - The investigation will prioritize pharmacies with significant discrepancies in drug pricing or high settlement amounts, utilizing data from insurance settlements and public complaints [1] Group 2: Enforcement Measures - Pharmacies found to be violating healthcare service agreements through "yin-yang pricing" will face consequences based on the severity of the violation, including potential suspension of insurance settlements and revocation of service agreements [2] - There will be a focus on pharmacies that implement discriminatory pricing based on different settlement methods or offer additional rebates to uninsured patients [2] - Serious cases involving significant amounts related to "yin-yang pricing" will be subject to heightened scrutiny and may be included in a flying inspection program [2]